Company / EPS (Basic)
RAPT Therapeutics, Inc. EPS (Basic) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$3.19
FY2024
5-year range
-$3.19 / -$2.53
FY2021-FY2024
Trend
-4.6%
vs FY2023
Sector context
#154 of 207
Health Care
What the data says
At $-3.19, RAPT Therapeutics, Inc.'s eps (basic) ranks #154 of 207 in the Health Care sector. EPS (Basic) has declined for 3 consecutive years, from $-2.53 in FY2021 to $-3.19 in FY2024.
Based on SEC 10-K filings.
-3.19 in FY2024.
Declined from $-2.58 to $-3.19 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#154 of 207 in Health CareTop 74% of 207This company -$3.19 Sector average -$0.42
▼
-661.7% below sector average
Key checks
Key Insights
- RAPT Therapeutics, Inc.'s eps (basic) has declined for 3 consecutive years.
- In FY2024, eps (basic) decreased 4.6% year-over-year.
- Ranks #154 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$3.19 | -4.6% |
| FY2023 | -$3.05 | -18.2% |
| FY2022 | -$2.58 | -2.0% |
| FY2021 | -$2.53 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026